Here is part of an article at
Seattle-based biotech Dendreon is hoping to get U.S. approval for the first cancer drug that would train the body to fight off cancer on its own, with few side effects. But researchers, statisticians and Wall Street analysts are fiercely debating whether there is enough data about this radical new treatment.
Dendreon's (nasdaq: DNDN - news - people ) Provenge is a so-called cancer vaccine. Researchers prefer the term immunotherapy because it would treat, not prevent, cancer. A personalized drug, composed of human immune system cells, is created for each patient; the idea is to give the immune system the tools it needs to fight off the disease.
No comments:
Post a Comment